FDA Opioid Action Plan Means More Advisory Committees And A New Look At REMS, PMRs
This article was originally published in RPM Report
Executive Summary
FDA announced February 4 that it is undergoing a “far-reaching action plan” to assess its approach to opioid medications in a bid to resolve one of the final obstacles blocking confirmation of Robert Califf as FDA Commissioner.